quinta-feira , 21 outubro 2021
Capa » 2021 » julho » 15

Arquivo Diário: 15/07/2021

Byondis Appoints Timo van den Berg as Senior Director, Immuno-Oncology R&D

Byondis Appoints Timo van den Berg as Senior Director, Immuno-Oncology R&D

Nijmegen, the Netherlands – 15 July 2021– Byondis B.V. today announced the appointment of Timo K. van den Berg, Ph.D., as senior director, Immuno-Oncology (IO) Research and Development. Van den Berg will assume this role on September 1, operating out of Byondis’ headquarters in Nijmegen.

In his new role, Van den Berg will be instrumental in helping shape Byondis’ IO pipeline, which includes the anti-SIRPα monoclonal antibody BYON4228.

“We are pleased to welcome Timo to the Byondis family. He is a globally recognized IO pioneer, having made important contributions to the field, such as being the first to describe the role of SIRPα and recognizing the potential to use this target to develop a drug for the benefit of cancer patients,” said Byondis Chief Scientific Officer Wim Dokter, Ph.D.
As a longstanding Byondis collaborator, Professor van den Berg played a pivotal role in the discovery of the CD47-SIRPα axis as an innate immune checkpoint. CD47 is known in the IO space as the “don’t eat me” signal that allows tumors to escape recognition and destruction.

“I am very excited about this new chapter in my career,” said Professor van den Berg. “I believe that Byondis and I are well matched. We share the same values, including a strong, goal-oriented work ethic, and a passion for improving patients’ lives by creating precision medicines targeting difficult-to-treat cancers.”

Van den Berg brings to Byondis more than 30 years of experience in the IO field — as a renowned researcher, educator, inventor, lecturer and coauthor of over 175 peer-reviewed publications. His most recent position was head and principal investigator, Immunotherapy Laboratory, Department of Molecular Hematology at Sanquin Research, Amsterdam, the Netherlands. Since 2017, Van den Berg has been professor of Immunotherapy, Vrije Universiteit, which is affiliated with the Department of Molecular Cell Biology and Immunology, Amsterdam University Medical Center. He spent 25 years as research group leader and department head at Amsterdam University Medical Center and Sanquin Research. Sanquin, a non-profit organization responsible for the blood supply in the Netherlands, also develops and produces pharmaceutical products, conducts scientific research and develops and performs diagnostic services.

Van den Berg is a member of many boards, including Amsterdam Infection and Immunity Institute and Cancer Center Amsterdam. His professional memberships include the Dutch Society of Immunology and the European Society for Clinical Investigation. He received his Ph.D. from Amsterdam’s Vrije Universiteit, and his M.Sc. in Biological Sciences (cum laude) from the University of Amsterdam.

About Byondis Leia Mais »

Anvisa divulga dados das séries históricas entre 2015 e 2019 da indústria farmacêutica

Organizado pela Secretaria-Executiva da Câmara de Regulação do Mercado de Medicamentos (SCMED), documento traz estatísticas sobre a indústria de fármacos em 2019, além de séries históricas entre 2015 e 2019. Leia Mais »

DSM: Quatro indicações do uso de probióticos em crianças

Crianças saudáveis, pais felizes. Não é verdade? A boa alimentação é a base para o crescimento saudável. A qualidade e a variedade dos alimentos que são oferecidos têm um papel importante. Mas, mesmo assim, algumas doenças ocorrem e são comuns na infância. Leia Mais »

Fábrica da Kingspan Isoeste alcança números históricos

Inaugurada há sete meses, unidade catarinense produz cerca de 200 mil m² de telhas e painéis por mês.

Leia Mais »

AGL CARGO fecha parcerias com companhias para garantir espaço para o mercado farmacêutico

Com a redução da oferta de disponibilidade de espaço para transporte internacional, a AGL Cargo se estabelece como pioneira em reservar alocação em voos com o objetivo de garantir o embarque de matérias-primas e manter o abastecimento de insumos, garantindo que não falte matérias-primas para a produção de medicamentos no Brasil. Leia Mais »

Aspen Pharma mostra preocupação com o meio ambiente

A Aspen Global, preocupada com o meio ambiente, firmou o compromisso de reduzir em 25% a emissão de gases do efeito estufa (GEE) até 2030. Leia Mais »

Fale com os gestores